Compare SXC & GOSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SXC | GOSS |
|---|---|---|
| Founded | 1960 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Steel/Iron Ore | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 549.5M | 615.7M |
| IPO Year | N/A | 2019 |
| Metric | SXC | GOSS |
|---|---|---|
| Price | $6.88 | $2.16 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 7 |
| Target Price | ★ $10.00 | $8.83 |
| AVG Volume (30 Days) | 984.7K | ★ 5.5M |
| Earning Date | 02-17-2026 | 03-12-2026 |
| Dividend Yield | ★ 6.01% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.75 | N/A |
| Revenue | ★ $1,843,100,000.00 | $44,051,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.94 | $6.41 |
| P/E Ratio | $10.66 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $6.24 | $0.76 |
| 52 Week High | $10.08 | $3.87 |
| Indicator | SXC | GOSS |
|---|---|---|
| Relative Strength Index (RSI) | 33.96 | 36.22 |
| Support Level | $7.98 | $2.24 |
| Resistance Level | $8.43 | $2.50 |
| Average True Range (ATR) | 0.34 | 0.22 |
| MACD | -0.10 | -0.01 |
| Stochastic Oscillator | 22.62 | 2.48 |
SunCoke Energy Inc operates as an independent producer of coke in the Americas. Its coke is primarily used as a principal raw material in the blast furnace steelmaking process as well as in the foundry production of casted iron. The company operates through three segments: Domestic Coke, Brazil Coke, and Logistics. It offers metallurgical and thermal coal. The company also provides handling and/or mixing services to steel, coke, electric utility, coal producing, and other manufacturing-based customers. The majority of revenue is derived from the Domestic Coke segment.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.